7-Azaindole-3-acetic acid derivatives: Potent and selective CRTh2 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 16, 2009, Pages 4794-4798

  Sandham, David A ^a   Adcock, Claire ^a   Bala, Kamlesh ^a   Barker, Lucy ^a   Brown, Zarin ^a   Dubois, Gerald ^a   Budd, David ^a   Cox, Brian ^a   Fairhurst, Robin A ^a   Furegati, Markus ^b   Leblanc, Catherine ^a   Manini, Jodie ^a   Profit, Rachael ^a   Reilly, John ^a   Stringer, Rowan ^a   Schmidt, Alfred ^b   Turner, Katharine L ^a   Watson, Simon J ^a   Willis, Jennifer ^a   Williams, Gareth ^a   Wilson, Caroline ^a   more..

^a Novartis Institutes of Biomedical Research   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Allergic diseases; Azaindole; CRTh2; Eosinophils; Prostaglandin D2

Indexed keywords

7 AZAINDOLE 3 ACETIC ACID DERIVATIVE; ACETIC ACID DERIVATIVE; PROSTAGLANDIN D2; PROSTAGLANDIN D2 RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROTEIN CRTH2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; EOSINOPHIL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; NONHUMAN; RAT;

ACETIC ACIDS; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; EOSINOPHILS; HUMANS; MICROSOMES, LIVER; PERMEABILITY; PYRIDINES; RATS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 67651094080     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.06.042     Document Type: Article

References (27)

1. Murray J.J., Tonnel A.B., Brash A.R., Roberts L.J., Gosset P., Workman R., Capron A., and Oates J.A. N. Engl. J. Med. 315 (1986) 800
2. Pettipher R., Hansel T.T., and Armer R. Nat. Rev. Drug Disc. 6 (2007) 313
3. Lukacs N.W., Berlin A.A., Franz-Bacon K., Sasik R., Sprague L.J., Ly T.W., Hardiman G., Boehme S.A., and Bacon K.B. Am. J. Physiol. 295 (2008) L767
4. Boehme S.A., Franz-Bacon K., Chen E.P., Sasik R., Sprague L.J., Ly T.W., Hardiman G., and Bacon K.B. Int. Immunol. 21 (2009) 81
5. Sugimoto H., Shichijo M., Iino T., Manabe Y., Watanabe A., Shimazaki M., Gantner F., and Bacon K.B. J. Pharmacol. Exp. Therap. 305 (2003) 347
6. Sawyer N., Cauchon E., Chateauneuf A., Cruz R.P.G., Nicholson D.W., Metters K.M., O'Neill G.P., and Gervais F.G. Br. J. Pharmacol. 13 (2002) 1163
7. Hirai H., Tanaka K., Takano S., Ichimasa M., Nakamura M., and Nagata K. J. Immunol. 168 (2002) 981
8. Armer R.E., Ashton M.R., Boyd E.A., Brennan C.J., Brookfield F.A., Gazi L., Gyles S.L., Hay P.A., Hunter M.G., Middlemiss D., Whittaker M., Xue L., and Pettipher R. J. Med. Chem. 48 (2005) 6174
9. Birkinshaw T.N., Teague S.J., Beech C., Bonnert R., Hill S., Patel A., Reakes S., Sanganee H., Dougall I.G., Phillips T.T., Salter S., Schmidt J., Arrowsmith E.C., Carrillo J.J., Bell F.M., Paine S.W., and Weaver R. Bioorg. Med. Chem. Lett. 16 (2006) 4287
10. Crosignani S., Page P., Missotten M., Colovray V., Cleva C., Arrighi J.-F., Atherall J., Macritchie J., Martin T., Humbert Y., Gaudet M., Pupowicz D., Maio M., Pittet P.-A., Golzio L., Giachetti C., Rocha C., Bernardinelli G., Filinchuk Y., Scheer A., Schwarz M.K., and Chollet A. J. Med. Chem. 51 (2008) 2227
11. Medina J.C., and Liu J. Ann. Rep. Med. Chem. 41 (2006) 221
12. Sandham D.A., Aldcroft C., Baettig U., Barker L., Beer D., Bhalay G., Brown Z., Dubois G., Budd D., Bidlake L., Campbell E., Cox B., Everatt B., Harrison D., Leblanc C.J., Manini J., Profit R., Stringer R., Thompson K.S., Turner K.L., Tweed M.F., Walker C., Watson S.J., Whitebread S., Willis J., Williams G., and Wilson C. Bioorg. Med. Chem. Lett. 17 (2007) 4347
13. Desarbre E., Coudret S., Meheust C., and Merour J.-Y. Tetrahedron 53 (1997) 3637
14. McKew J.C., Foley M.A., Thakker P., Behnke M.L., Lovering F.E., Sum F.-W., Tam S., Wu K., Shen M.W.H., Zhang W., Gonzalez M., Liu S., Mahadevan A., Sard H., Khor S.P., and Clark J.D. J. Med. Chem. 49 (2006) 135
15. Topliss J.G. J. Med. Chem. 15 (1972) 1006
16. Roberts M.S., Magnusson B.M., Burczynski F.J., and Weiss M. Clin. Pharmacokinet. 41 (2002) 751
17. Young R.N. Prog. Med. Chem. 38 (2001) 249
18. Valko K., Nunhuck S., Bevan C., Abraham M.H., and Reynolds D.P. J. Pharm. Sci. 92 (2003) 2236
19. Values calculated using clogp v4.71, BioByteCorp, Claremont, CA, USA.
20. Jelfs S., Ertl P., and Selzer P. J. Chem. Inf. Model. 47 (2007) 450
21. Kratochwil N.A., Huber W., Mueller F., Kansy M., and Gerber P.R. Curr. Opin. Drug Discovery Dev. 7 (2004) 507
22. Waring M.J. Bioorg. Med. Chem. Lett. 19 (2009) 2844
23. Zhou S., Chan E., Duan W., Huang M., and Chen Y.-Z. Drug Metab. Rev 37 (2005) 41
24. 4S requires C, 52.38; H, 3.1; N, 10.78; S, 8.23. Found C, 52.76; H, 3.353; N, 10.46; S, 8.053.
25. Bala, K.; Leblanc, C.; Sandham, D.A.; Turner, K. L.; Watson, S.J.; Brown, L.N.; Cox, B. PCT Int. Appl. WO2005123731, 2005; Chem. Abstr. 2005, 144, 88269.
26. Brown, L.N.; Leblanc, C.; Sandham, D.A; Singh, H.P.; PCT Int. Appl. WO 2007065683, 2007; Chem. Abstr. 2007, 147, 72640.
27. Sandham, D.A. PCT Int. Appl. WO2007065684, 2007; Chem. Abstr. 2007 147, 72634.